anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention provides a method of treating BPH using modified pore-forming proteins (MPPs). These MPPs are derived from naturally occurring cytotoxic proteins (nPPs) that kill cells by forming pores or channels in the cell membrane, resulting in cell death. The MPPs are generated by modification of the nPPs such that they are capable of being selectively activated at normal prostate cells. Such modification may include the addition of a prostate-specific protease cleavage site to the activation sequence, and/or the addition of a prostate-specific targeting domain to allow selective targeting of prostate cells. These MPPs are capable of selectively targeting and killing normal prostate cells in vivo. The MPPs may be used either alone or in combination with other therapies for the treatment of BPH.
This is the single arm of this study. Patients with non-CF bronchiectasis will provide 1) an induced sputum sample after inhaling 15 ml of 0.9% NaCl solution and 2) a blood sample.
Physical activity is associated with a variety of positive health outcomes, as well as improved metabolic profiles and reduced inflammation. However, levels of moderate to vigorous physical activity (MVPA) diminish dramatically as children move into the middle school years. To address this problem, this study tests a behavioral intervention, called "Zamzee," designed to motivate middle school-aged children to increase their levels of MVPA. The Zamzee intervention consists of a 3-axis accelerometer that tracks individual physical activity rates over time and a website that displays individual physical activity rates and provides rewards for maintaining or improving physical activity rates. The primary aim of this randomized, controlled trial is to test whether middle school-aged children randomly assigned to the Zamzee intervention will show significantly greater levels of physical activity levels over six months, compared with control group participants who wear the accelerometer but have no access to the rewards website. A secondary aim is to test the intervention's impact on biological parameters that may contribute to the long-term health effects of inactivity (including C-reactive protein as a measure of inflammation, and hemoglobin-A1C as a measure of metabolic status) in a sub-set of study participants who agree to provide blood samples.
ETHNOPHARMACOLOGICAL RELEVANCE: The use of medicinal plants for central nervous system (CNS)-related ailments, such as epilepsy and anxiety, is prevalent in South Africa. Plants from the Lamiaceae family are commonly used for their therapeutic benefits. Leonotis leonurus (L.) R.Br. has been reported in ethnobotanical literature to have anticonvulsant and anxiolytic effects through the inhalation of pyrolysis products obtained by combustion of the aerial parts.
AIM AND OBJECTIVES: To explore the chemical profiles and CNS activity of the smoke extract and isolated constituents of L. leonurus in zebrafish larvae, through anticonvulsive and anxiolytic activity assays.
MATERIALS AND METHODS: The smoke extract of L. leonurus was obtained through the combustion of the aerial parts of the plant using a custom-built smoke recovery apparatus. The chemical profile of the smoke constituents was determined using Ultra-Performance Liquid Chromatography coupled with Mass Spectrometry (UPLC-MS). Targeted compounds were subjected to preparative High-Performance Liquid Chromatography for separation before structure elucidation using Nuclear Magnetic Resonance (NMR). The maximum tolerated concentrations, as well as the anxiolytic activity of the smoke extract were determined in five days post fertilisation zebrafish larvae. Reverse-thigmotaxis and locomotor activity of larvae in the light/dark transition assay were used to determine anxiolytic activity. Zebrafish larvae at six days post fertilisation (dpf) were subjected to several concentrations of the smoke constituents of L. leonurus. The baseline locomotor activity of the larvae was tracked for 30 min, prior to addition of pentylenetetrazole (PTZ) to induce seizure-like behaviour in the larvae, after which the locomotor activity of the larvae was once again tracked for an additional 30 min.
RESULTS: The UPLC-MS profiles of the smoke extract revealed the presence of two main compounds, leoleorin A and leoleorin B, which were targeted and isolated. Upon subjection to NMR spectroscopy for structure elucidation, the compounds were confirmed to be labdane diterpenoids. Both leoleorin A and leoleorin B, and the smoke extract displayed suppression of the PTZ induced seizure-like behaviour in zebrafish larvae. Under light and dark conditions, the smoke extract and compounds displayed potential anxiolytic activity at different concentrations.
CONCLUSION: Our results suggest that the smoke constituents of L. leonurus may exert anticonvulsant and anxiolytic effects which align with the traditional indications and the mode of administration.
AcrySof Monofocal IOL Model SN60AT implanted in the capsular bag in the posterior chamber following cataract removal and intended for long-term use over the lifetime of the cataract patient. Both eyes will be implanted (bilateral implantation).
PURPOSE:To provide the subject new microorganisms belonging to Bacillus licheniformis, capable of degrading aflatoxin, useful for mycota growth inhibitors for preventing agricultural crop disease control, fermentation promoters for mitigating odor generation for livestock feces, or livestock growers, etc. CONSTITUTION:The objective microorganisms containing, as active ingredients, microorganisms belonging to Bacillus licheniformis and capable of degrading aflatoxin [e.g. Bacillus licheniformis DB-9011 (FERM BP-3418)]. The microorganisms are mixed with entirely aged waste sawdust used for artificial Lyophyllum aggregatum culture, thus obtaining (A) mycota growth inhibitors for e.g. pathogenic mould, capable of agricultural crop disease control through application on soil or plants, (B) fermentation promoters capable of mitigating odor generation through application on e.g. livestock feces or addition to aerating tanks, or (C) livestock growers capable of promoting nutrient absorption through the digestive tracts, steadily increasing livestock weight and increasing egg production by administration to livestock.
Participants will be asked to meditate every day just before going to bed for at least 10 min/session. Participants can use any sleep meditations which can be found by clicking on the "meditate" tab and then "sleep". Particpiants will be asked to not choose any general meditations including the Daily Calm or Sleep Stories.
BACKGROUND AND AIMS: The development and morphology of crop plants have been profoundly altered by evolution under cultivation, initially through unconscious selection, without deliberate foresight, and later by directed breeding. Wild wheats remain an important potential source of variation for modern breeders; however, the sequence and timing of morphological changes during domestication are not fully resolved.
METHODS: We grew and measured 142 wheat accessions representing different stages in wheat evolution, including three independent domestication events, and compared their morphological traits to define the morphospace of each group.
KEY RESULTS: The results show that wild and domesticated wheats have overlapping morphospaces, but each also occupies a distinct area of morphospace from one another. Polyploid formation in wheat increased leaf biomass and seed weight but had its largest effects on tiller loss. Domestication continued to increase the sizes of wheat leaves and seeds and made wheat grow taller, with more erect architecture. Associated changes to the biomass of domesticated wheats generated more grains and achieved higher yields. Landrace improvement subsequently decreased the numbers of tillers and spikes, to focus resource allocation to the main stem, accompanied by a thicker main stem and larger flag leaves. During the Green Revolution, wheat height was reduced to increase the harvest index and therefore yield. Modern wheats also have more erect leaves and larger flower biomass proportions than landraces.
CONCLUSIONS: Quantitative trait history in wheat differs by trait. Some trait values show progressive changes in the same direction (e.g. leaf size, grain weight), whereas others change in a punctuated way at particular stages (e.g. canopy architecture), and other trait values switch directions during wheat evolution (e.g. plant height, flower biomass proportion). Agronomically valued domestication traits arose during different stages of wheat history, such that modern wheats are the product of >10 000 years of morphological evolution.
The aim of this study will be to verify the effect of creatine supplementation associated to clinical treatment of the functional capacity in patients with intermittent claudication. The sample will be composed by patients with intermittent claudication of both sexes. The patients will be ramdomized in a double-blind procedure to receive during seven days (loading) and posteriorly 49 days (maintenance) a creatine (Cr) supplementation or placebo (PLA), associated to the clinical treatment. Before ("baseline"), after "loading" period and after the maintenance period of supplementation, the patients will go through a functional capacity evaluation. The fuctional capacity evaluation will be evaluated by a six minute-walking test. For statistical analysis it will be used the ANOVA of two factors for repeated measurements, having the (Cr and PLA) group and the time (pre, post-loading and post-maintenance), and when needed the post-hoc of Newman keuls. The adopted level of significance will be P\<0.05.
ABSTRACT     This invention relates to novel water in oil emulsions. The emulsions of this invention are translucent water in oil emulsions comprising a water phase containing a humectant, an oil phase comprising petroleum jelly and the like and an emulsifying agent to give a water in oil emulsion; the aqueous phase having a refractive index in essentially the same range as the oil phase.  The trans-lucent water in oil of this invention have the same general appearance and feel of petroleum jelly and func-tion like petroleum jelly but are superior thereto in the sense that when applied to skin will not only help prevent water from escaping therefrom or exist a barrier effect, but also, will allow water humectants and other moistur-izers from the emulsion water phase to pass therethrough to contact the skin and to moisturize the skin.  The compositions of this invention are useful as skin moistur-izer compositions.  They may be used as a carrier or vehicle for oil and water soluble topical drugs.  They also may be used in the same general way as petrolatum (e.g. skin protectant agent, emollient, lubricant, etc.)
This study is designed to collect long-term safety information on infliximab, from patients with COPD who participated in research studies using this drug. The primary COPD studies include C0168T54 (in the U.S.) and two small studies in Europe (EU0016 C0168X09 and EU0073 C0168X57). All patients who had at least one dose of study drug in those studies are being asked to participate in this long-term safety follow-up study which will provide important information about the study drug. The long-term effect of the study drug on new cancers and survival will be evaluated from data collected over a 5-year period which begins from each patient's last safety visit in the primary study. Data for this study will be collected at study entry and twice yearly thereafter up to a maximum of 5 years from each patient's last safety visit in the primary study. The last safety visit in the primary study is defined as the last visit for each subject during which adverse events (AEs)s are recorded in the primary study.Twice yearly, all participating study sites will be reminded to complete the electronic charts for each participating patient. At study entry, the following will be performed: (1) Medical history and physical examination, including ear, nose, and throat (ENT) examination performed by a qualified physician; (2) Chest x-ray(posterior and lateral), unless performed within 3 months prior to enrollment and (3) CT (computer imaging) scan of the chest (spiral preferred), unless performed within 6 months prior to enrollment. In addition, data will be collected at study entry on the use of commercial infliximab or any other anti-tumor necrosis factor (anti-TNF) agent subsequent to the last safety visit in the primary study. At each patient's subsequent visit, data will be collected by either direct contact with the patient (office visit or telephone call), review of patient's medical records, contact with the patient's primary care physician or oncologist. At the final visit (5 years from each patient's last safety visit in the primary study), the following will be performed: (1) Medical history and physical examination, including ENT examination performed by a qualified physician; (2) Chest x-ray, unless performed within the previous 3 months, and (3) CT scan of the chest (spiral preferred), unless performed within the previous 6 months.

The primary outcome of this study is Number of patients with each of the following safety events: malignancy or death. The secondary outcome of this study is the number of patients with malignancies by malignancy type (ie, Hodgkin's lymphoma, non-Hodgkin's lymphoma, head and neck cancers, lung cancer, other malignancies). No drug is provided
A method for delivering a long term care message to a recipient includes gathering long term care information from a records repository and encoding at least some of the long term care information into predefined codes associated with predefined script segments. A script is generated using the script segments, and a human-understandable message is delivered to the recipient. A system for delivering a message related to long term care of a client serviced by an assisted living service provider includes an administration user interface enabling definition of script components that can be used to describe long term care of the client. A user associated with the assisted living service provider can record long term care information about the client. A script is generated using selected script components associated with the long term care information. A distributor module causes the script to be converted into a human-understandable message that is delivered to a message recipient.
Total anomalous pulmonary venous connection (TAPVC) is a rare congenital defect where pulmonary venous plexus fails to connect with the left atrium (LA). Surgical repair is the primary treatment for TAPVC, but factors influencing outcomes are not fully understood. This study investigates the early outcomes of surgical repair for TAPVC and associated factors. A retrospective cohort analysis was conducted on TAPVC patients who underwent surgical repair between 2012 and 2022. Data were collected from medical records and supplemented with phone call validation. Demographic characteristics, surgical data, diagnostic tests, and outcomes were analyzed. Statistical analysis included chi-square, t-tests, and multivariate logistic regression using SPSS. A total of 88 patients underwent surgical repair for TAPVC, resulting in a mortality rate of 21.6%. Weight and bypass time were significantly associated with patient survival. Female patients had a higher likelihood of death. The anatomic type did not significantly influence mortality. Patients with pulmonary venous obstruction (PVO) experienced a higher mortality rate. Notably, ligation of the vertical vein in supracardiac and infracardiac types was associated with lower mortality. In conclusion, our study identifies several key factors contributing to higher mortality rates following TAPVC surgery, including low weight, female gender, prolonged bypass time, and preoperative vein obstruction. Highlighting the significance of surgical technique, particularly the sutureless approach, we advocate for its meticulous consideration to achieve improved outcomes. Furthermore, our findings indicate a potential decrease in mortality associated with vertical vein ligation, which may mitigate the risk of post-repair heart failure. We suggest further rigorous studies to gain comprehensive insights into TAPVC surgical interventions.
A low-concentration atropine drug product and a manufacturing method therefor. The product comprises a packaging container having two cavities, wherein a first cavity and a second cavity are designed to be communicable and sealed. The product further comprises a first drug liquid placed in the first cavity and a second drug liquid placed in the second cavity. During use, the two cavities are in communication by means of destroying a sealing structure between the first cavity and the second cavity, so that the first drug liquid and the second drug liquid are mixed into a mixed drug liquid. The mixed drug liquid contains 0.005-0.2% of an active ingredient, 0-3.5% of a buffer system, 0-5% of an osmotic pressure regulator and the balance of water. According to the present invention, the low-concentration atropine is used in combination with a new packaging container. The main drug end only comprises atropine and a buffer solution, the dilution end comprises a buffer solution and the osmotic pressure regulator, and during use, a main drug solution and a dilution solution are uniformly mixed. Therefore, both the stability of the low-concentration atropine and the sterility and comfort of use thereof are ensured.
The present invention provides an isolated fully human monoclonal anti-HIV antibody, wherein said antibody is PGC14 having a heavy chain comprising the amino acid sequence of SEQ ID NO: 37 and a light chain comprising the amino acid sequence of SEQ ID NO: 38. The heavy chain CDRs of the PGC14 antibody have the following sequences per Kabat and Chothia definitions: SGYSFIDYYLH (SEQ ID NO: 116), LIDPENGEARYAEKFQ (SEQ ID NO: 117), and AVGADSGSWFDP (SEQ ID NO: 118). The light chain CDRs of the PGC14 antibody have the following sequences per Kabat and Chothia definitions: SGSKLGDKYVS (SEQ ID NO: 120), ENDRRPSG (SEQ ID NO: 121), and QAWETTTTTFVF (SEQ ID NO: 44). Furthermore, the invention provides a method for producing this broadly neutralizing antibody (bNab), comprising (i) culturing an immortalized B cell clone expressing the antibody and (ii) isolating the antibody. Moreover, the invention provides a pharmaceutical composition comprising the antibody of the invention and at least a pharmaceutically acceptable carrier. According to the invention, the antibody can be used in,  e.g.,  immunizing or reducing the effect of an HIV-infection or an HIV-related disease or for post-exposure prophylaxis; in a method of screening polypeptide libraries for polypeptides that can induce an immune response against HIV; or in immunizing an individual against a plurality of HIV-1 species.
1,241,656. 3-Etherified cephalosporin derivatives. GLAXO LABORATORIES Ltd. 6 Aug., 1968 [21 Aug., 1967], No. 38493/67. Headings C2A and C2C. [Also in Divisions A5-A6] Novel 7#-acylamino-3-etherified hydroxymethyl-ceph-3-em-4-carboxylic acids are prepared either (a) by N-acylating the corresponding 7#-amino-3-ether, which compounds are also novel, e.g. by reaction with an acid halide, anhydride or mixed anhydride, an active ester or azide, or an acid together with an esterifying agent; or (b) by reacting a 7#- acylamido - 3 - PCH 2  - ceph - 3 - em - 4 - carboxylic acid, wherein P is a group replaceable by an ether group, with an etherifying agent, optionally followed by N-deacylation and reacylation with a different acyl group, preferably by the method of Specification 1,241,655. P may be either a hydroxy or an acetoxy group. When P is hydroxy, etherification may be effected either directly, by reacting the compound with an orthoester such as MC(OR) 3  wherein M is hydrogen, alkyl or -OR and R is the required etherifying radical, or with a diazo compound, or an unsaturated compound activated by electron donating or attracting groups; or indirectly by first converting the 3-hydroxymethyl group to a 3-CH 2 X group where the corresponding acid HX has a pKa of not more than 4, and then reacting the 3- CH 2 X containing compound with an alcohol or phenol to convert X to the required ether group. The group X may be an ester group formed by esterifying the CH 2 OH group with, e.g. halo-, methoxy-, alkylthio-, or cyanoacetic acid, phenyl- or substituted phenylglyoxylic acid or glyoxylic acid itself, phenylpropiolic acid or formic acid; other examples of X are halogen, thio-ether groups, and isothiocyanate groups. When P is acetoxy, this group may be directly displaced by reaction with an alcohol or phenol in a polar medium to give the corresponding ether. In many of these procedures, the 4-carboxyl and 7#-amino group (if present), and any other carboxyl or amino substituent groups present, are protected by easily removable groups, e.g. urethane, trityl, arylmethylene, sulphenyl or enamine groups; alternatively the carboxyl group may be esterified and reaction conditions used wherein the NH 2  group remains protonated. D(-) - α - Formyloxy - α - phenylacetyl chloride is prepared by refluxing in benzene a mixture of D(-)-mandelic acid, p-toluenesulphonic acid and formic acid, to give D(-)-α-formyloxy-α- phenylacetic acid, which is isolated and then refluxed in benzene with thionyl chloride to give the required product.
Animal feed for poultry was prepd. by adding ginseng or processed ginseng, vitamins, and calcium into basal feed. Thus, wheat bran 5, crushed rice 20, corn powder 45, soya draff 20, fish meal 10 parts were mixed with 30 parts water to yield basal feed. Ginseng draff powder 1.3 g, Vit A 16000 I.U., Vit B6 2mg, choline.HCl 1500mg, and calcium 8.4 % were mixed with 1kg basal feed to yield feed compn. for a laying hen. 10 heads of hens were fed on this compn. and the weight and appearance of eggs obtd. was tested. The average weight per egg was 74g and the quality was good.
Persons with disabilities (PwD) commonly experience fatigue, which adversely impacts their everyday lives. Information to manage and improve fatigue can be complicated and overwhelming. Little has been done to link mobile health (mHealth) approaches with patient activation and self-management to effectively address fatigue for PwD. The purpose of this study is to develop and pilot-test a fatigue self-management short message service (SMS) text intervention using mobile phones to target patient activation levels in PwD. The proposed study will: (1) develop content for a fatigue self-management intervention using SMS tailored to patient activation levels in persons with multiple sclerosis, spinal cord injury, and stroke. An advisory board made up of one physical medicine and rehabilitation physician and six PwD will provide input on the content and format for the developed content. (2) test the feasibility and acceptability of SMS to improve patient activation for fatigue self-management in PwD. The long-term goal is to improve the health of PwD by increasing their skills, confidence, and knowledge to manage fatigue and other chronic symptoms that affect their daily life.